Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

Physician perception and opinion regarding EGFR rash among mCRC patients treated with Vectibix

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Survey
Study drug and medical condition

Name of medicine, other

Vetibix

Medical condition to be studied

Rash
Population studied

Short description of the study population

Oncologists (i.e.: licensed and practicing oncologist) were recruited from the M3 Global Research database who had treated at least three new or continuing metastatic colorectal cancer patients with panitumumab in the last year.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Colorectal cancer patients

Estimated number of subjects

250
Study design details

Main study objective

Describe oncologist’s opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed. Describe oncologist’s perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.

Data analysis plan

The proportion of patients who select each answer within a survey question will be summarized and confidence intervals will be estimated as the estimated proportion ± 1.96 multiplied by the estimated standard error. We will stratify our analysis by the following variables:• Primary hospital affilation (academic/university hospital, community non-teaching hospital, and community teaching hospital).• Size of practice setting (>20 doctors, 6-20 doctors, <5 doctors, solo practice).• Number of new or continuing metastatic colorectal cancer patients the oncologist personally treated (stratify at the median number of patients reported by the participating oncologists).
Documents
Study results
English (74.49 KB - PDF)View document